Business
Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets
Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities.The upgrade program is...
About this update from Rapid Dose Therapeutics Corp
[{"type":"text","content":"Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities.","length":495,"tagName":"p"},{"type":"text","content":"The upgrade program is focused on advancing the facility toward compliance with Health Canada Drug Establishment Licence (DEL) requirements, a critical regulatory pathway for companies engaged in the manufacturing, packaging, testing, distribution, and commercialization of pharmaceutical products in Canada. These enhancements are expected to support production of products requiring a Drug Identification Number (DIN), a key authorization for prescription and over-the-counter drug sales in regulated markets.","length":511,"tagName":"p"},{"type":"text","content":"Strategic Move Into Pharmaceutical Manufacturing and Global Drug Markets","length":72,"tagName":"p"},{"type":"text","content":"The Burlington facility upgrades mark a significant step in Rapid Dose Therapeutics' evolution from a drug delivery innovation company into a pharmaceutical manufacturing and commercialization platform. The initiative is designed to expand the Company's capabilities across oral thin film drug delivery, pharmaceutical production, and global distribution channels, supporting its proprietary QuickStrip™ fast-dissolving oral thin film technology.","length":454,"tagName":"p"},{"type":"text","content":"QuickStrip™ is engineered to deliver pharmaceuticals, nutraceuticals, cannabinoids, vaccines and nicotine products through rapid absorption via the oral mucosa, offering advantages in bioavailability, onset time, and patient compliance compared to traditional capsules, tablets, injections and inhalation-based delivery systems.","length":328,"tagName":"p"},{"type":"text","content":"GMP and EU GMP Alignment Supports International Expansion","length":57,"tagName":"p"},{"type":"text","content":"In parallel, Rapid Dose is upgrading its existing cannabis production clean rooms to align with Good Manufacturing Prac...